HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triclosan Concern In Congress Spurs Call For Final Antimicrobial Monograph

This article was originally published in The Rose Sheet

Executive Summary

Concern about the safety of triclosan has Rep. Ed Markey pressuring FDA to finalize the OTC Topical Antimicrobial Drug monograph, first proposed in 1972

You may also be interested in...



Consent Decree Orders FDA Action On Triclosan OTC Monographs

A Nov. 21 consent decree sets multiple deadlines over a five-year period to make FDA finalize its OTC topical antimicrobial drug products monograph with respect to triclosan. Under a pair of deadlines of note to triclosan product makers, the agency must publish a tentative final monograph for consumer antiseptic hand-wash products by Dec. 16, with a final monograph due Sept. 15, 2016.

FDA Regulatory Agenda Targets Antimicrobial Hand Washes, Sunscreen

Triclosan use in consumer hand-wash products could be addressed by FDA in a proposed rule targeted for February release. Sunscreen also is identified as a priority in the agency’s semi-annual regulatory agenda.

Researchers Call For Reduced Triclosan Use Following NIH-Funded Study

Industry has come out against a study exploring the impact of triclosan on cardiac and skeletal muscle function in animals, which they say is a “publicity campaign” and used “unrealistically large” doses of the anti-bacterial ingredient that do not represent real-world conditions. The NIH-funded study prompted investigators to call for a “dramatic reduction” in the ingredient’s use in consumer products.

Related Content

UsernamePublicRestriction

Register

RS016661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel